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RÉSUMÉ
Atrophie musculaire spinale de Werdnig-Hoffmann: 
deux rapports de cas et revue de la litterature 
Introduction. L’atrophie musculaire spinale de type 
I appartient au groupe des maladies neuromusculaires 
autosomiques récessives caractérisées par la dégénéres-
cence des cellules des cornes antérieures de la moelle 
épinière, qui entraîne à son tour une faiblesse muscu-
laire symétrique et une atrophie musculaire. Chez 95% 
d’enfants, on observe une mortalité précoce jusqu’à 
l’âge de 2 ans.
Rapports de cas. Nous présentons 2 cas cliniques 
de trouble de Werdnig-Hoffmann chez les enfants de 
la région de Tchernivtsi, en Ukraine, et faisons une 
analyse de la littérature sur cette pathologie. Deux cas 
d’atrophie musculaire sont présentés. Le matériel a été 
compilé conformément aux normes éthiques appli-
cables aux essais cliniques (Association médicale mon-
diale, Déclaration d’Helsinki, Principes éthiques pour 
les recherches médicales humaines). On a utilisé des 
méthodes généalogiques et moléculaires génétiques, des 
tests sanguins biochimiques, ENMG. La maladie de-
vrait être suspectée chez les bébés si l’anamnèse indique 
un faible mouvement fœtal pendant la grossesse. Une 
ABSTRACT
Introduction. Spinal muscular atrophy type 1 is an 
autosomal recessive neuromuscular disorder character-
ized by degeneration of the anterior horn cells in the 
spinal cord, leading to symmetric muscle weakness and 
atrophy. 95% of affected children die before 2 years 
of age. The annual incidence in the world has been 
estimated at around 1/11 000. The errors (mutations) 
in the SMN1 gene prevalence vary from 1: 38 to 1: 70 
in the population. The disorder is primarily caused by 
the homozygous deletions of the gene (5q12.2-q13.3). 
The SMN gene mutation is primarily caused by a ho-
mozygous deletion in exons 7 or 8.
Case presentations. 2 clinical cases of children with 
the Werdnig-Hoffmann disorder will be presented, 
and a literature review of this pathology. Two cases 
of spinal muscular atrophy diagnosed in Chernivtsi 
region, Ukraine, are presented. In both children, a 
molecular genetic analysis found the homozygous de-
letions of SMN1 gene in exons 7 and 8. Most affected 
children die within 2.3- 1.3 years of age. These two 
cases ended lethally due to subinfection. Material was 
collected in accordance with ethical standards of work 
person under Helsinki Declaration (World Medical 
Association Declaration of Helsinki, Ethical Principles 
REVIEW
SPINAL MUSCULAR ATROPHY (WERDNIG-HOFFMANN 
ATROPHY/DISEASE): TWO CASE PRESENTATIONS AND 
LITERATURE REVIEW
Ryznychuk M. Aleksandrovna1, Kryvchanska M. Ivanivna1, Lastivka I. Volodymyrivna1, 
Khmara T. Volodymyrivna1, Goncharenko V. Anatoliyivna1
1 Higher State Educational Institution of Ukraine „Bukovinian State Medical University“, Chernivtsi, 
Ukraine
Address for correspondence:
Ryznychuk Mariana Alexandrovna
Nezavisimosti Ave., 95/27
Chernivtsi, Ukraine, 58005
e-mail: rysnichuk.mariana@gmail.com; phone +38 050 192 09 53
Archives of the Balkan Medical Union
June 2018 / 15
INTRODUCTION
Spinal muscular atrophy (SMA) is a group of 
hereditary disorders characterized by progressive de-
generation of motor neurons of the anterior horns of 
spinal cord1. There are proximal forms, which occur 
more often, and distal spinal muscular atrophy1,2. The 
frequency of proximal forms of SMA is 80-85%, and 
distal – about 10%1. 
At present, 5 types of proximal SMA are distin-
guished, depending on the time when clinical mani-
festations appeared: 
  SMA 0, the most severe form, which manifests it-
self intrauterinely; 
  SMA I, severe form of Werdnig-Hoffmann disor-
der (OMIM 253300), clinically manifested in the 
first 6 months of life and which ends lethally in 
the first two years; 
  SMAII, intermediate form (OMIM 253550), pa-
tients live longer than 4 years; 
  SMA III, Kugelberg-Welander disorder, juvenile 
form (OMIM 253400) progressive muscle weakness 
develops after 2 years; 
  SMA IV, adult form (OMIM 271150)1,3,4.
SMA was first described by G. Werdnig in 1891, 
who presented a clear description of pathomorpho-
logical changes in various groups of muscles, periph-
eral nerves and symmetric atrophy of the cells of 
anterior horns of spinal cord and ventral roots, and 
also made assumptions about the hereditary nature 
of the disorder. A year later, J. Hoffmann identified 
SMA as an independent nosological unit. In 1893, 
G. Werdnig and J. Hoffmann presented a description 
of 7 cases from 4 families and showed that the cause 
of the disorder is the degeneration of the cells of the 
anterior horn of the spinal cord5. 
The genes responsible for the disorder develop-
ment are localized in the region of the chromosome 
5q12.2-q13.3. Four genes, whose damage causes the 
deve lopment of the disorder and determines its sever-
ity, are localized h ere1.
The most common mutation in the SMN gene 
is presented as a deletion of the 7 or 8 exons in th e 
homozygous state6. The mutation in telomeric copy 
of the SMN gene is a necessary, but insufficient condi-
tion for th e disorder, as the descriptions of healthy 
people with such a mutation in a homozygous state 
are known1.
hypotension prononcée et une hypotrophie des mus-
cles, une absence de réflexes tendineux sur les membres 
inférieurs, une fibrillation des muscles de la langue et 
des doigts sont notées dans la période néonatale, La 
principale cause de décès est l’insuffisance respiratoire 
dans le contexte de maladies respiratoires intercur-
rentes. L’article présente deux cas d’atrophie musculaire 
spinale de Werdnig-Hoffmann. La délétion des 7ème 
et 8ème exones du gène SMN1 à l’état d’homozygote a 
été détectée chez les deux enfants. La durée de vie des 
enfants a été de 2,3 et 1,3 ans. Conclusions. Ces deux 
cas se sont terminés par la mort des enfants en rapport 
avec l’addition d’une infection intercurrente.
Mots-clés: maladie de Werdnig-Hoffmann, amyotro-
phie spinale, SMN1 et SMN2, enfants.
for Medical Research Involving Human Subjects). 
Genealogical analysis of families, biochemical analy-
sis of blood, ENMG were carried out. The molecular 
genetic method was used: DNA was extracted and 
the deletions of 7 and 8 exons of the telomeric SMN 
gene were tested by PCR method. The disorder usually 
manifests in young children, if mother has a history 
indicating a weak fetal movement during pregnancy. 
Hypotension and hypotrophy of muscles, absence of 
tendon reflexes on lower extremities, fibrillation of 
the muscles of the tongue and fingers are observed in 
the neonatal period. Children with this pathology can 
poise their heads, but never turn over and do not sit. 
They are characterized by a „frog“ position: the limbs 
are laid in the shoulder and femoral joints and bent in 
elbow and knee joints. Chest distortions are pathogno-
monic. The main cause of death is respiratory distress 
associated with intercurrent respiratory disorders. 
Conclusion. Based on the literature data and our ex-
perience of monitoring children with SMA type I, the 
disorder has a malignant rapidly progressing course.
Key words: Werdnig-Hoffmann disease, spinal mus-
cular atrophy, SMN1 and SMN2 gene, children. 
Abbreviations. PCR – polymerase chain react ion; 
ENMG – electroneuromyography; SMA – Spinal 
Muscular Atrophy.
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Gene – NAIP (a neuronal apoptosis inhibitor 
gene, OMIM: 600355), whose deletions of one or 
more exons in homozygous state occur in 40-70% of 
patients with SMA type I6,7. In patients with deletion 
of the 7 and 8 exons of the SMN-gene in a homozy-
gous state, a violation in the NAIP gene is detected 
simultaneously8,9,10. The third gene – H4F5 is located 
next to the SMN gene. It is assumed that its deletion 
or mutations are responsible for the severity of the 
clinical course of various types of SMA2. 
BTF2p44 is the fourth gene responsible for emer-
gence of the disorder. About 15% of patients with 
SMA have the deletion of this gene in the heterozy-
gous state.
The factors determining the severity of the clini-
cal pic ture are: a) the number of centromeric copies 
of the SMN gene (2 – for type I of SMA and 3-5 – for 
II and III types of SMA); the simultaneous presence 
of deletion in the NAIP, H4F5, BTF2p44 genes11. 
Most of the SMA are inherited by an autosomal 
recessive type. Gene SMN (survival motor neuron 
ge ne), represented by two highly homologous copies 
(telomeric –  SMN1 and centromeric – SMN2). In 90% 
of patients with different types of spinal atrophy, the 
deletion of the SMN1 gene in 7 an d 8 exons is re-
corded. The coding sequence of SMN2 differs from 
SMN1 with one nucleotide in exon 7 (840C-T), its 
replacement results in a decrease in the transcription 
and deficiency of the normal stable SMN protein. 
Approximately 94% of SMA people lack both cop-
ies of the SMN1-exon 7, which leads to significant 
 protein loss. Loss of exon 7 may be the result of de-
letion or duplication of 840C-T, which, in essence, 
transforms SMN1 into SMN2 (by genetic conver-
sion). Losing SMN1 can also occur from other rea-
sons, such as large deletions or point mutations. Most 
of the SMN protein is synthesized from the SMN1 
gene. The SMN2 gene provides about 1/10 of  the to-
tal amount of functional protein in the cell6,8.
The protein encoded by the SMN gene consists 
of 294 amino acids and is expressed in all body tis-
sues. The vast majority of protein is found in the 
motor neurons of the anterior horns of the spinal 
cord. SMN-protein of peripheral motor neurons has 
the following functions: participates in the process 
of mRNA; participates in the transport of mRNA in 
the axons of motor neurons; modulates the growth 
of axons and the dynamics of the cytoskeleton; SMN 
also plays an important role in maturation of axon 
terminals in muscles after childbirth; as a result of 
mutations in the SMN1 gene, peripheral motor neu-
rons lose the ability to control the transition from 
preRNA to mRNA and produce the proteins neces-
sary for their survival and functioning8,12,13.
The authors14 have shown that the reduced level 
of SMN proteins changes the expression of the mi-
croRNA and their distribution in neurons. In par-
ticular, the levels of microRNA-183 are increased 
in SMN-deficient neurons. The depression of the 
expression of microRNA-183 in the spinal cord in 
the model of SMA mice increases life expectancy and 
improves the function of motor neurons. 
It has been shown that in different human popu-
lations, the incidence of SMA type 1 varies from 1 
to 6,000-11,000, or approximately 7.8-10 per 100,000 
live births. The estimated incidence of the disorder 
in the world is 1 per 11,000 individuals. According 
to some data, the frequency of mutation of the SMN1 
gene in the human population ranges from 1:38 to 
1:7012. The reason for such a low morbidity rate may 
be that the genotype of some fetuses is characterized 
by the ratio of copies of the SMN1/SMN2 genes as 
0: 0 (that is, the SMN protein is not synthesized at 
all), which is known to cause fetal death in other 
species15,16. The Werdnig-Hoffmann SMA in Saratov 
region occurs with a frequency of 1.6 per 100,000 
population , in Uzbekistan – 0.26 per 100,000 pop-
ulation, in Kazakhstan – 0.87 per 100,000 popula-
tion. The prevalence of Werdnig-Hoffmann SMA in 
Switzerland is 1: 17000, in Denmark – 1:20 000, in 
To ronto – 1:160003.
The population-genetic research of Werdnig-
Hoffmann SMA was also conducted among the 
Ukrainian p opulation recently. In particular, it was 
found that the frequency of mutation carriers in exon 
7 of the SMN1 gene ( 840 C-T) was 3.24% (1:31)17. It 
should be noted that Ukraine is a multiethnic state18 
with a number of effects of population dynamics, 
such as migration19-22. This can lead to changes in the 
population frequencies of normal and pathological 
signs and the need for their continuous monitoring, 
as is the case, in particular, with respect to the SMA 
in other countries of the world23. 
THE PURPOSE OF THIS RESEARCH is to supplement 
the obtained population data with two clinical ca ses 
of Werdnig-Hoffmann disorder, in particular, their 
detailed description, which were discovered in the 
inhabitants of Northern Bukovina. 
CASE PRESENTATIONS
We present 2 clinical cases of children with the 
Werdnig-Hoffmann disorder, w hich are determined 
by the genetician of OCCH in Chernivtsi, Ukraine, 
in 2016. 
The material was collected in accordance with 
ethical standards of working person under Helsinki 
Declaration (World Medical Association Declaration 
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of Helsinki, Ethical Principles for Medical Research 
Involving Human Subjects).
The commission of biomedical ethics of the 
Bukovina State Medical University has not revealed 
vi olations of moral and legal rules in the conduct of 
medical scientific research.
Genealogical analysis of families, biochemical 
analysis of blood, ENMG were carried out. The mo-
lecular genetic method was used: DNA was extracted 
and the deletions of 7 and 8 exons of the telomeric 
SMN gene were tested by PCR method. 
For the purpose of molecular genetic analysis, 
DNA from the blood leukocyte nuclei was taken from 
patients with spinal muscular atrophy and their fam-
ily members. The informed consent for the study was 
obtained from all the patients. DNA was obtained by 
standard method – hydrolysis of cell lysates with pro-
teinase K, followed by phenolic extraction24. The pres-
ence of deletions of the 7 and 8 exons of the SMN1 
and SMN2 genes was performed after hy drolysis of the 
in vitro amplification products of the corresponding 
sequences of the restriction endonucleases of DraI 
and DdeI, respectively, at a temperature of 37°C for 
3-5 hours in 2% agarose gel25. Both amplification prod-
ucts of the 7 exon of the SMN1 and SMN2 genes have 
the same size – 188 bps. They are distinguished by the 
product of amplification of the 7 exon of the SMN2 
gene, which has a site recognized by the endonuclease 
restriction of DraI. In patients with SMA, with a ho-
mozygous deletion of the 7 exon of the SMN1 gene, 
only the hydrolyzed amplification products (fragments 
of 164 and 24 bps.) are detected on the electrophore-
sis, corresponding to the 7 exon of the SMN2 gene. 
If the electrophoresis showed an unhydrolyzed PCR 
product of 188 bps, this indicated a deletion of the 
7 exon of the SMN2 gene in this patient. Hydrolyzed 
(corresponding to the sequence of the SMN2 gene), 
as well as non-hydrolyzed amplification products (cor-
responding to the sequence of the SMN1 gene), have 
been identified in patients with at least one copy of 
the SMN1 or SMN2 genes. The amplification products 
of the 8 exon of the SMN1 and SMN2 genes also have 
the same size (189 bps). They differ only due to the 
fact that in the 8 exon of the SMN2 gene there is a 
cognition site for the restriction endonuclease DdeI. 
Therefore, if only these amplification products were 
determined on the electrophoresis, this indicated that 
the patient had no sequence of the 8 exon of the SMN1 
gene (homozygotes, patients with SMA). The presence 
of only one non-hydrolyzed fragment of 189 bps meant 
the absence of the sequence of the 8 exon of the SMN2 
gene in this individual. If, on the electrophoresis, both 
the hydrolyzed (corresponding to the SMN2 gene) and 
the non-hydrolyzed (corresponding to the SMN1 gene) 
amplification products were observed, this patient 
was a heterozygote and had at least one copy of the 
sequences of the 8 exon of the SMN1 and SMN2 genes. 
First case. A family with a two-year-old child, who 
was born from the third uncomplicated pregnancy, 
ended with physiological delivery, presented to the 
genetician. The mother’s maternal grandmother and 
mother’s blood brother are heterozygous carriers of 
mutatio ns in the 7 and 8 exons of the telomeric SMN 
gene; the mother’s brother born from the second mar-
riage has been diagnosed with the type III SMA. The 
weight at birth – 4000 g, body length – 54 cm. From 
the history, we found out that in 3 months she began 
to poise her head, did not sit, did not stand. By the end 
of 9 months, the mother drew attention to a decrease 
in motor activity, muscle weaknes s. On examination, 
muscle tone is reduced. Tendon reflexes from the lower 
extremities were not activated. Abdominal reflexes are 
absent, the re are no pathological reflexes. Muscle hy-
potension is detected. At 4.5 months, the girl stopped 
poising her head. She doesn’t bear against her legs. The 
abdominal respiration type, the intercostal muscles al-
most do not participate in the act of b reathing. The 
cranial nerves: III, IV, VI pairs – without pathology, 
bulbar disturbances. The diffuse muscu lar hypotonia, 
arreflexia, the „frog“ position are found, active move-
ments in the limbs are not found. The osteoarticular 
system: „chicken breast“ chest distortion, hip dysplasia.
From the age of 1 month, anemia was diagnosed, 
hemoglobin levels were low until the age of one year. 
The girl was breastfed, the weight gain corresponded 
to the age. At the age of 5 months, she suffered acute 
nasopharyngitis, at the age of 6 months – acute phar-
yngitis. First teeth from 6 months. 
Vaccinations: BCG, against viral hepatitis B 
(three times), against infantile paralysis (three times), 
DTP (twice). The child has been regularly observed by 
pediatrician and examined by narrow specialists.
In the biochemical blood analysis: an increase in 
the activity of creatine phosphokinase up to 9.10 μc/L 
(normal value up to 3.4 μg/L), the content of lactate is 
normal (1.54 mmol/l). The results of electroneuromyo-
graphy (ENMG) revealed the signs of diffuse motor 
neuropathy. 
Indicative ENMG-picture allowed the suspicion 
of a hereditary disorder of the nervous system. The 
Werdnig-Hoffmann spinal atrophy was diagnosed phe-
notipically. 
During the genetic testing, the deletion of exons 
7-8 of SMN gene in homozygous state was revealed, 
which confirmed the diagnosis.
 At the age of 2.2 years, she was admitted to the 
pediatric department with respiratory failure on the 
background of acute respiratory infections, followed 
by arrhythmic breathing, so the patient was trans-
ferred to the intensive care unit on the artificial lung 
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ventilation apparatus. During the whole hospitali-
zation time, the child was in a clear consciousness. 
Despite the treatmen t, the state remained without 
any positive dynamics. Constantly, she was on ALV, 
lung-heart failure was constantly progressing. The 
child died at the age of 2 years and 3 months.
Second case. A one-year and two months old 
girl was admitted as emergency to the department of 
intensive care of the Children’s Municipal Clinical 
Hospital in Chernivtsi, Ukraine, with complaints of 
shortness of breath, lack of movements in the legs, 
hypotrophy of the lower extremities.
Genealogical history – parents are healthy, from 
the first pregnancy in the same marriage a girl wh ose 
illness had similar symptoms was born and died at the 
age of 1 year and 4 months (pathological diagnosis: 
Werdnig-Hoffmann spinal muscular atrophy, acute 
cardiovascular insufficiency).
From the history: child from the 2nd pregnancy, 
without pathology, 2nd delivery at 39 weeks of ges-
tation. She was born with a weight of 3500 g. From 
birth, mother drew attention to silent crying, reducing 
muscle tone, the child (lying on her stomach) did not 
raise her head and arms above the shoulder level. 
Starting from 2 months of age, the child experi-
enced a progressive decrease in motor activity, weight 
loss, loss of motor skills, ceased to poise her head. 
There was diffuse muscular hypotension, absence 
of tendon reflexes from the lower extremities, the 
„frog“ position. After neurological treatment, there 
was a short-term positive dynamics in the form of im-
provement of motor activity. 
According to the conclusion of a board of doc-
tors, with the involvement of pediatricians and resusci-
tators, the condition of the child was treated as an un-
specified myopathic disorder with respiratory failure. 
Neurological status: clear consciousness, quiet 
crying. Cranial nerves: the fixed sight, followed the 
subject, bulbar disturbances, hypomimia. There were 
fasciculations of the tongue, diffuse muscular hypo-
tension to atony in the legs, areflexia, the „frog“ posi-
tion. The chest almost didn’t participate in the act of 
breathing, transferred into artificial lung ventilation. 
Pulmonary exam – pneumonia.
Due to the critical condition of the child, it was 
not possible to perform ENMG. The DNA analysis 
revealed deletions of the 7 and 8 exons of the telom-
eric SMN1 gene in the homozygous state. Conclusion: 
spinal muscular atrophy, type I. In the dynamics, the 
child’s condition deteriorated due to the progression 
of respiratory and cardiovascular insufficiency, neuro-
logical symptoms, intoxication. The fatal outcome was 
due to the development of multiple organ failure at the 
age of one year and three months. 
 In the first and second case, the anatomopatho-
logical diagnosis was: Werdnig-Hoffmann spinal mus-
cular atrophy. Dystrophic degenerative changes in 
the neurons of the nuclei of the medulla oblongata, 
the anterior and posterior horns of the spinal cord. 
Pneumonia. Polyorganic insufficiency.
DISCUSSION
The pathogenesis of SMA type I is associated 
with progressive degeneration of the motor neurons 
of the anterior horns of the spinal cord (in some cases, 
the motor cornea of the brain stem too). Due to the 
genetic defect, the programmed cell death emerges, as 
well as violations of axonogenesis. Loss of motor neu-
rons leads to the development of flaccid paralysis and 
denervation atrophy of transversally strained muscles. 
In most cases, symmetrical lesions of the proximal 
muscles of the extremities are detected. Distal amyo-
trophy, lesions of bulbar musculature and deficiency 
asymmetry develop less frequently. Central motor 
neurons are intact. There are no sensory disturbances. 
The intelligence is saved5,17,18. 
Type I SMA manifests itself up to 6 months of 
age and has a rapidly progressing course. 
From the medical history, the mother indicates 
a weak fetal movement during pregnancy. In the neo-
natal period, marked hypotension and hypotrophy of 
the muscles, absence of tendon reflexes, fibrillation 
of the muscles of the tongue and fingers are detected. 
Children with this pathology can poise their heads, 
but never turn over and do not sit. They are charac-
terized by a „frog“ position: the limbs are laid in the 
shoulder and femoral joints and bent in elbow and 
knee joints. The muscles of the proximal parts of the 
lower extremities are the first to be involved into the 
pathological process.  Then, hypotonia of muscles ex-
tends in upward type. Indicative bone deformities 
(saddle-shaped, sunken chest, as well as scoliosis and 
kyphosis in the chest and lumbar spine). In evolution, 
with the progression of the lesion, it extends to the 
muscles innervated by the bulbar group of the cranial 
nerves.  Often, vegetative disorders appear in the form 
of moderate distal hyperhidrosis.
If muscle weakness occurs immediately after 
birth, death occurs at about 6 months of age, whereas 
when the first symptoms appear after 3 months of 
life, the life span can be about 2 years, only 10-12% 
of SMA children live longer than 5 years19. The main 
cause of death is respiratory failure on the background 
of intercurrent respiratory disorders. 
The genetic method, which consists in determin-
ing the deletion of 7 and/or 8 exons in the SMN1 
gene, is the „gold standard“ for diagnosis13,20. The de-
letions in the specified areas of the gene, in a patient 
in a homozygous state, confirm the diagnosis of SMA. 
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In the absence of deletion, a quantitative analy-
sis of the number of copies of the SMN genes, by a 
multiplex ligase reaction method, with subsequent 
amplification, should be conducted2. The following 
electrophysiological methods are used:  needle electro-
myography, the study of muscle response caused by 
electrical stimulation and the estimation of the num-
ber of motor units.  These methods are proposed for 
monitoring the course of SMA1.  Electromyographic 
(EMG) SMA marker: characteristic signs of denerva-
tion due to motor neuron defeat: spontaneous rhyth-
mic activity („rhythm of the palisade“), potentials of 
fibrillation and fasciculations, positive sharp waves, 
changes in the potentials of motor units, with forma-
tion of gigantic polyphase potentials, and a decrease 
in the number of motor units19.
Biochemical markers in patients with SMA are: 
activity of creatine phosphokinase in blood serum, 
which can exceed the normal value by 2-4 times, but 
not more than 10 times. In the morphological study of 
muscles, specific signs of muscle damage are revealed: 
clusters of diminished fibers (beam atrophy), which 
alternate with sections of hypertrophic fibers1. 
 The current treatment method for SMA is the 
use of anti-sense oligonucleotides (ASOs) directed 
against sequences that usually suppress the inclusion 
of the 7th exon of the SMN2 gene. This is one of the 
promising therapeutic approaches to SMA treatment. 
The ASOs demonstrated the ability to increase the in-
clusion of 7 exon in the transcript of the matrix RNA 
(mRNA) SMN2 and the development of a complete 
SMN protein.
Isis Pharmaceuticals (USA) has already com-
pleted the Phase I-II ASO trials (SPINRAZA medica-
tion) at SMA, which indicates the safety and potential 
efficacy of this therapeutic approach.  SPINRAZA is 
administered by an intrathecal injection that provides 
drug penetration directly into the cerebrospinal fluid 
(CSF). At present, the company is working on two 
clinical trials of Phase III21-23.
CONCLUSIONS
 Thus, based on the literature data and our expe-
rience of monitoring children with SMA type I, the 
disorder has a malignant rapidly progressing course.
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